0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-L1

PD-L1

PD-L1 Molecule Information

Name:Programmed death-ligand 1
Target Synonym:Programmed Cell Death 1 Ligand 1,PDCD1L1,B7H1,PDL1,Programmed Death Ligand 1,B7-H1,B7-H,B7-H1 Antigen,CD274,B7 homolog 1,PDCD1 ligand 1,PD-L1,PDCD1LG1,CD274 Molecule,CD274 Antigen,HPD-L1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:59
Lastest Research Phase:Approved

PD-L1 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PD1-H82A3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Mouse IgG2a Fc,Avitag™
PD1-H82A3-structure
PD1-H52H3 Human Human PD-L1 / B7-H1 (19-134) Protein, His Tag (MALS verified)
PD1-H52H3-structure
PD1-H52H3-sds
PD1-H52H3-elisa_1
PD1-C52H3 Canine Canine PD-L1 / B7-H1 Protein, Fc Tag
PD1-C52H3-structure
PD1-C52H3-sds
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
PDL-H82E4-structure
PDL-H82E4-sds
PDL-H82E4-elisa_1
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin
PDL-H5250-structure
PDL-H5250-sds
PDL-H5250-elisa_1
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PDL-H82F2-structure
PDL-H82F2-sds
PDL-H82F2-elisa_1
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin
PD1-M52A2-structure
PD1-M52A2-sds
PD1-M52A2-elisa_1
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (recommended for biopanning, MALS verified)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-H82E5-elisa_1
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M82F5-elisa_1
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag
PD1-M5220-structure
PD1-M5220-sds
PD1-M5220-elisa_2
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag
PD1-M5251-structure
PD1-M5251-sds
PD1-M5251-elisa_1
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-H52A3-hplc
PD1-H52A3-elisa_1
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C52H4-elisa_1
PD1-C52H4-elisa_2
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag
PD1-C5253-structure
PD1-C5253-sds
PD1-C5253-elisa_1
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H82F3-elisa_1
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Strep Tag
PD1-H5282-structure
PD1-H5282-sds
PD1-H5282-elisa_1
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5258-hplc
PD1-H5258-elisa_1
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-H5229-structure
PD1-H5229-sds
PD1-H5229-hplc
PD1-H5229-elisa_1
PD1-H5229-elisa_2

PD-L1 Part of Bioactivity data

PD1-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat.No. PD1-H82F3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 1 μg/mL (Routinely tested).

PD1-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat. No. PD1-H82F3) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing anti-PD-1 antibody. The concentration of PD-L1 used is 2 μg/mL. The IC50 is 0.64 μg/mL (Routinely tested).

PD1-M5220-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD1-M5220-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-L1, His Tag (Cat. No. PD1-M5220) on CM5 Chip via Anti-His antibody can bind Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) with an affinity constant of 1.37 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD-L1 Customer Reviews

PD-L1 Molecule Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

PD-L1 Molecule Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

PD-L1 References

PD-L1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Atezolizumab 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A; RO-5541267 Approved Genentech Inc 泰圣奇, Tecentriq United States Melanoma s:13:"Genentech Inc"; 2016-05-18 Fallopian Tube Neoplasms; Microsatellite Instability; Cholangiocarcinoma; Urologic Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Thymoma; Neoplasms, Unknown Primary; Lymphoma; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Lymphoma, Non-Hodgkin; Breast Neoplasms; Leukemia, Myeloid, Acute; Urogenital Neoplasms; Carcinoma, Squamous Cell; Uterine Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Adenocarcinoma; Liposarcoma, Myxoid; Kidney Diseases; Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours; Kidney Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Merkel Cell; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Liver Neoplasms; Papillomavirus Infections; Details
Avelumab PF-06834635; MSB-0010718C Approved Merck Serono Bavencio United States Carcinoma, Renal Cell s:14:"Emd Serono Inc"; 2017-03-23 Lymphoma, Large B-Cell, Diffuse; Uterine Cervical Neoplasms; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Chordoma; Solid tumours; Papillomavirus Infections; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Glioblastoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms Details
Durvalumab MEDI-4736; 28X28X9-OKV (UNII code) Approved Medimmune Llc 英飞凡, Imfinzi Mainland China Carcinoma, Non-Small-Cell Lung s:18:"Astrazeneca Uk Ltd"; 2018-02-16 Esophageal Squamous Cell Carcinoma; Lymphoma, Follicular; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Multiple Myeloma; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Digestive System Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms Details

PD-L1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Durvalumab/Gefitinib Phase 2 Clinical Medimmune Carcinoma, Non-Small-Cell Lung Details
GNC-038 GNC-038 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CX-072 CX-072 Phase 2 Clinical Cytomx Therapeutics Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma Details
Human source and Fc engineered monoclonal antibody (MabSpace) MSB-2311 Phase 1 Clinical Mabspace Biosciences Neoplasms Details
LY-3415244 LY-3415244 Phase 1 Clinical Eli Lilly And Company Neoplasms Details
FS 118 FS-118 Phase 1 Clinical Merck Serono, F-Star Hematologic Neoplasms; Neoplasm Metastasis Details
BMS-986189 BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 Phase 1 Clinical Bristol-Myers Squibb Company Sepsis Details
KD-045 (Nanjing KAEDI Biotech) KD-045 Phase 1 Clinical Nanjing Kaedi Biotechnology Co Ltd Neoplasms Details
KL-A167 A-167; KL-A167; HBM-9167 Phase 2 Clinical Sichuan Kelun Botai Biomedicine Co Ltd Lymphoma, B-Cell; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
BGB-A333 BGB-A333 Phase 2 Clinical Beigene Ltd Neoplasms Details
艾姆地芬 Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences Solid tumours Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details
ALPN-202 ALPN-202 Phase 1 Clinical Alpine Immune Sciences Lymphoma Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) Phase 1 Clinical Jiangsu Huaiyu Pharmaceutical Co Ltd Neoplasms Details
JS-003 JS-003 Shanghai Junshi Biosciences Co Ltd Solid tumours Details
GS-4224 GS-4224 Phase 2 Clinical Gilead Sciences Inc Neoplasms; Hepatitis B Details
INBRX-105 INBRX-105 Phase 1 Clinical Inhibrx Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Esophageal adenocarcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Anti PD-L1 monoclonal antibody (Biocad) BCD-135 Phase 1 Clinical Biocad Neoplasms Details
ES101 ES101 Phase 1 Clinical Inhibrx Neoplasms Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) Phase 1 Clinical The Second Hospital Of Nanjing Medical University Carcinoma, Hepatocellular Details
HLX-20 HLX-20 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Neoplasms Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Neoplasms Details
BMS-936559 MDX-1105; BMS-936559 Phase 3 Clinical Bristol-Myers Squibb Company Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
RG-6084 RG-6084 Phase 1 Clinical F. Hoffmann-La Roche Ltd Hepatitis B Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Neoplasms Details
IGV-001 IGV-001 Phase 2 Clinical Thomas Jefferson University Glioblastoma Details
IBI-323 IBI323; IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
Pd-1-pik Pd-1-pik Phase 1 Clinical Department Of Integrative Medicine, Huashan Hospital Of Fudan University, Shanghai, China Glioblastoma Details
LOR-S03 CDX-527; LOR-A04; LOR-S01; LOR-S03 Phase 1 Clinical Celldex Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Durvalumab/Selumetinib sulfate Phase 1 Clinical Astrazeneca Plc Neoplasms Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Phase 1 Clinical Sichuan University Peritoneal Neoplasms Details
CA-170 CA-170; AUPM-170 Phase 2 Clinical Aurigene Solid tumours; Neoplasms Details
CK-301 CK-301 Phase 1 Clinical Dana-Farber Cancer Institute Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
ADG-104 ADG-104; ADG104 Phase 2 Clinical Neoplasms Details
ND-021 ND-021; NM21-1480 Phase 2 Clinical Numab Therapeutics Ag Solid tumours; Neoplasms Details
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
PM-8001 6MW3111; PM-8001 Phase 2 Clinical Pumis Biotechnology (Zhuhai) Co Ltd Solid tumours; Lung Neoplasms Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) LP-002 Phase 2 Clinical Taizhou Houde Aoke Technology Co Ltd Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma Details
GR-1405 GR-1405 Phase 2 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Head and Neck Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Lymphoma Details
SHR-1701 SHR-1701 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) ZKAB001; STI-A1014; STIA-1014 Phase 3 Clinical Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd Biliary Tract Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Osteosarcoma; Bile Duct Neoplasms; Uterine Cervical Neoplasms Details
GEN-1046 GEN1046; PD-L1x4-1BB; DuoBody-PD-L1x4-1BB Phase 2 Clinical Biontech Se, Genmab Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
ABL-503 ABL-503 Phase 1 Clinical Abl Bio Inc Solid tumours Details
Carrizumab Details
Cosibelimab CK-301; TG-1501 Phase 3 Clinical Tg Therapeutics Lymphoma; Carcinoma, Non-Small-Cell Lung Details
89Zr-durvalumab Phase 2 Clinical Radboud University Nijmegen Head and Neck Neoplasms Details
Lodapolimab LY-3300054 Phase 1 Clinical Eli Lilly And Company Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
18F-BMS-986192 BMS-986192-[18F] Clinical Bristol-Myers Squibb Company Neoplasms Details
FAZ-053 LAE-005; FAZ-053 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Glioma Details
MT-6402 Phase 1 Clinical Molecular Templates Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
IBI318 IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
IBI-322 IBI-322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasms Details
KN-046 KN046; KN-046 Phase 3 Clinical Suzhou Alphamab Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Thymus Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) HS-636 Phase 2 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Primary mediastinal B cell lymphoma Details
IMC-001 IMC-001; STI-3031; STI-A1015 Phase 2 Clinical Sorrento Therapeutics Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
TQB-2450 APL-502; CBT-502; TQ-B2450 Phase 3 Clinical Cbt Carcinoma, Ovarian Epithelial; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Cholangiocarcinoma; Stroke; Solid tumours; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Genital Diseases, Female; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Liver Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms Details
SHR-1316 SHR-1316 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop